Tucatinib with trastuzumab and capecitabine for treating HER2-positive unresectable locally advanced or metastatic breast cancer after 2 or more anti-HER2 therapies - A Single Technology Appraisal
Tucatinib with trastuzumab and capecitabine for treating HER2-positive unresectable locally advanced or metastatic breast cancer after 2 or more anti-HER2 therapies - A Single Technology Appraisal
This report is a critique of the company’s submission (CS) to NICE from Seagen on the clinical effectiveness and cost effectiveness of tucatinib (TUKYSA®) with trastuzumab and capecitabine for treating HER2-positive unresectable locally advanced or metastatic breast cancer after two or more anti-HER2 therapies. It identifies the strengths and weakness of the CS. Clinical experts were consulted to advise the evidence review group (ERG) and to help inform this report.
National Institute for Health and Care Research
Scott, David Alexander
19b5fd34-9974-4ae4-8be0-27a693639e20
Hazell, Lorna
1c9036d8-13c0-4fe1-88be-9a926dc003b5
Colquitt, Jill L.
b5872647-bc73-47d1-be44-8d1170eddbc6
Kalita, Neelam
da42f168-a3cc-44c9-bafb-2801ff57914b
Lord, Joanne
fd3b2bf0-9403-466a-8184-9303bdc80a9a
Loveman, Emma
a2363b23-8798-4b6e-90ca-c768848e6e02
Shepherd, Jonathan
dfbca97a-9307-4eee-bdf7-e27bcb02bc67
2021
Scott, David Alexander
19b5fd34-9974-4ae4-8be0-27a693639e20
Hazell, Lorna
1c9036d8-13c0-4fe1-88be-9a926dc003b5
Colquitt, Jill L.
b5872647-bc73-47d1-be44-8d1170eddbc6
Kalita, Neelam
da42f168-a3cc-44c9-bafb-2801ff57914b
Lord, Joanne
fd3b2bf0-9403-466a-8184-9303bdc80a9a
Loveman, Emma
a2363b23-8798-4b6e-90ca-c768848e6e02
Shepherd, Jonathan
dfbca97a-9307-4eee-bdf7-e27bcb02bc67
Scott, David Alexander, Hazell, Lorna, Colquitt, Jill L., Kalita, Neelam, Lord, Joanne, Loveman, Emma and Shepherd, Jonathan
(2021)
Tucatinib with trastuzumab and capecitabine for treating HER2-positive unresectable locally advanced or metastatic breast cancer after 2 or more anti-HER2 therapies - A Single Technology Appraisal
(Health Technology Assessment, HTA - NIHR134065)
Southampton.
National Institute for Health and Care Research
119pp.
Record type:
Monograph
(Project Report)
Abstract
This report is a critique of the company’s submission (CS) to NICE from Seagen on the clinical effectiveness and cost effectiveness of tucatinib (TUKYSA®) with trastuzumab and capecitabine for treating HER2-positive unresectable locally advanced or metastatic breast cancer after two or more anti-HER2 therapies. It identifies the strengths and weakness of the CS. Clinical experts were consulted to advise the evidence review group (ERG) and to help inform this report.
Text
Tucatinib ERG report
Restricted to Repository staff only
Request a copy
More information
Published date: 2021
Identifiers
Local EPrints ID: 454186
URI: http://eprints.soton.ac.uk/id/eprint/454186
PURE UUID: 732c33c1-85e7-404d-bba2-827195ab6dbd
Catalogue record
Date deposited: 01 Feb 2022 18:08
Last modified: 11 Sep 2024 02:26
Export record
Contributors
Author:
David Alexander Scott
Author:
Jill L. Colquitt
Author:
Emma Loveman
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics